Brief: Lantern Pharma And Starlight Therapeutics Announce FDA Clearance Of Ind For A Planned Phase 1 Pediatric Cns Cancer Trial Of Star-001
27/03/2026 11:52
Lantern Pharma Inc LTRN.O: LANTERN PHARMA AND STARLIGHT THERAPEUTICS ANNOUNCE FDA CLEARANCE OF IND FOR A PLANNED PHASE 1 PEDIATRIC CNS CANCER TRIAL OF STAR-001 LANTERN PHARMA INC - TRIAL TO EVALUATE STAR-001 ALONE AND WITH SPIRONOLACTONE IN PEDIATRIC CNS CANCERS LANTERN PHARMA INC - TRIAL PLANNED WITH POETIC CONSORTIUM ACROSS 14 CANCER CENTERS IN US, CANADA, ISRAEL Source text: ID:nBw5fY5r7a Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments